Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®
The Journal of Headache and Pain, 19 gennaio 2024

2) Self-discharge during treatment for acute recreational drug toxicity: an observational study from emergency departments in seven European countries
International Journal of Emergency Medicine, 29 novembre 2023

3) Sex Differences in Outcomes of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Preadmission Use of Antiplatelets
CNS Drugs, 28 marzo 2023

4) Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®
Cephalalgia, aprile 2023

5) Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
iScience, 20 gennaio 2023

6) Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Science, 20 ottobre 2022

7) Spikevax booster and delayed urticaria: a Swiss signal with diagnostic uncertainties due to a high proportion of direct patient reports
European Journal of Clinical Pharmacology, 18 ottobre 2022

8) ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
Science, 12 agosto 2022

9) P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2
Frontiers in Medicine, 7 luglio 2022

10) Reply to Gremese et al.: Statistical reasoning to evaluate treatment effects when data are collected with lack of design: Covid-19 experience
PNAS Proceedings of th National Academy of Sciences of the United States of America, 15 febbraio 2022

11) Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
PLoS One, 10 febbraio 2022

12) Broad betacoronavirus neutralization by a stem helix-specific human antibody
Science, 3 settembre 2021

13) Effect of Medication Reconciliation at Hospital Admission on 30-Day Returns to Hospital: A Randomized Clinical Trial
JAMA Network Open, 1 settembre 2021

14) Concentrations of Seven Phthalate Monoesters in Infants and Toddlers Quantified in Urine Extracted from Diapers
International Journal of Environmental Research and Public Health, 24 giugno 2021

15) The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination
Journal of Thrombosis and Haemostasis, 8 giugno 2021

16) Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
Science, 18 maggio 2021

17) Reply to the Letter to the Editor by Kessler Y et al. regarding the manuscript "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database."
Cephalagia, 2 maggio 2021

18) Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland
The Lancet Regional Health - Europe, febbraio 2021

19) The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement
Current Therapeutic Research, 1 aprile 2021

20) Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase
Cancers, 6 marzo 2021

21) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Cell, 28 gennaio 2021

22) Pros and Cons in Using Population-Based Registers for Assessing the Fetal Safety of Drugs
JAMA Pediatrics, 19 gennaio 2021

23) Isotonitazene: Fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland
Forensic Science International, 13 gennaio 2021

24) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database
Cephalalgia, 12 gennaio 2021

25) Safety profile of anti-calcitonin gene-related peptide monoclonal antibodies in pregnancy, lactation and fertility: analysis of the WHO global pharmacovigilance database
Reproductive Toxicology, ottobre 2020

26) A data-driven approach to identify risk profiles and protective drugs in COVID-19
PNAS Proceedings of the National Academy of Sciences of the United States of America, 10 dicembre 2020

27) Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
Cancers, 23 novembre 2020

28) False-positive urine screen test for MDMA in a patient exposed to mebeverine
British Journal of Clinical Pharmacology, 16 novembre 2020

29) Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Cell, https://www.cell.com/cell/fulltext/S0092-8674(20)31234-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420312344%3Fshowall%3Dtrue

30) Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients
Endocrine, https://link.springer.com/article/10.1007/s12020-020-02465-4

31) Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data
Scientific Reports, https://www.nature.com/articles/s41598-020-70653-3

32) MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014-2017
Clinical Toxicology, https://www.tandfonline.com/doi/abs/10.1080/15563650.2020.1784914?journalCode=ictx20

33) Clinical Characteristics and Management of a Liver Transplanted Patient Admitted With SARS-CoV-2 Infection
Clinics and Research in Hepatology and Gastroenterology, https://www.sciencedirect.com/science/article/pii/S2210740120301595?via%3Dihub

34) Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
Frontiers in Pharmacology, https://www.frontiersin.org/articles/10.3389/fphar.2020.00557/full
Alessandro Ceschi
is Head of Research Programs [Rif. 20700]
at Istituto di Scienze Farmacologiche della Svizzera Italiana (ISFSI) (Rif. ISFSI)
Viale Officina 3 6500 Bellinzona